Current Status and Trends in Prophylaxis and Management of Anthrax Disease
Open Access
- 12 May 2020
- Vol. 9 (5), 370
- https://doi.org/10.3390/pathogens9050370
Abstract
Bacillus anthracis has been identified as a potential military and bioterror agent as it is relatively simple to produce, with spores that are highly resilient to degradation in the environment and easily dispersed. These characteristics are important in describing how anthrax could be used as a weapon, but they are also important in understanding and determining appropriate prevention and treatment of anthrax disease. Today, anthrax disease is primarily enzootic and found mostly in the developing world, where it is still associated with considerable mortality and morbidity in humans and livestock. This review article describes the spectrum of disease caused by anthrax and the various prevention and treatment options. Specifically we discuss the following; (1) clinical manifestations of anthrax disease (cutaneous, gastrointestinal, inhalational and intravenous-associated); (2) immunology of the disease; (3) an overview of animal models used in research; (4) the current World Health Organization and U.S. Government guidelines for investigation, management, and prophylaxis; (5) unique regulatory approaches to licensure and approval of anthrax medical countermeasures; (6) the history of vaccination and pre-exposure prophylaxis; (7) post-exposure prophylaxis and disease management; (8) treatment of symptomatic disease through the use of antibiotics and hyperimmune or monoclonal antibody-based antitoxin therapies; and (9) the current landscape of next-generation product candidates under development.Keywords
This publication has 121 references indexed in Scilit:
- Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation AnthraxAntimicrobial Agents and Chemotherapy, 2013
- Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure ProphylaxisClinical and Vaccine Immunology, 2013
- Anthrax Vaccine–Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol ChallengeScience Translational Medicine, 2012
- Recombinant Protective Antigen Anthrax Vaccine Improves Survival when Administered as a Postexposure Prophylaxis Countermeasure with Antibiotic in the New Zealand White Rabbit Model of Inhalation AnthraxClinical and Vaccine Immunology, 2012
- Anthrax Vaccine Antigen-Adjuvant Formulations Completely Protect New Zealand White Rabbits against Challenge with Bacillus anthracis Ames Strain SporesClinical and Vaccine Immunology, 2012
- Analysis of Antibody Responses to Protective Antigen-Based Anthrax Vaccines through Use of Competitive AssaysClinical and Vaccine Immunology, 2010
- Cellular and systemic effects of anthrax lethal toxin and edema toxinMolecular Aspects of Medicine, 2009
- Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey ModelAntimicrobial Agents and Chemotherapy, 2006
- Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthraxProceedings of the National Academy of Sciences of the United States of America, 2006
- Selection of Bacillus anthracis isolates resistant to antibioticsJournal of Antimicrobial Chemotherapy, 2004